Breast Cancer Research and Treatment **36**: 319, 1995.
© 1995 *Kluwer Academic Publishers. Printed in the Netherlands.*

Author index, Volume 36

Aubele M 83
Auer G 83
Auerbach L 11
Avril A 71

Baak JPA 49
Baldetorp B 23
Ballesta AM 41
Barbareschi M 181,205
Bendahl P-O 23
Bennen JN 49
Berry DA 35
Bevilacqua P 205
Bezwoda WR 61
Blaauw J 49
Bonichon F 71
Boracchi P 205
Borg Å 23
Bouck N 119
Boyd J 315
Brisson J 93
Burrows FJ 237

Cabot MC 299
Caffo O 205
Coindre J-M 71
Colley KJ 157
Conway T 315
Czubayko F 157

Dalla Palma P 181,205
Dansey RD 61
de Mascarel I 71
Duggan DB 35
Dupuis NP 227
Durand M 71

Emi Y 227
Engan T 282
Ewers S-B 23

Falkmer U 83
Fernö M 23
Ferrara 127
Filella X 41
Folkman J 109
Forti S 181
Fox SB 219

Gasparini G 103,181,205
Gatter KC 219
Giménez N 41
Giuliano AE 299
Goff D 227
Gundersen S 49

Hanak H 11
Hannisdal E 49
Harris AL 219
Hawkins MJ 253
Hayes DM 35
Heider K-H 307
Henderson IC 35
Herrlich P 307
Höfler H 83
Holden SA 227
Hsieh SS 157
Huot J 93

Ikebe M 227
Inada K 193

Jannink I 49
Johanessen DC 282
Jordan VC 267

Kakeji Y 227
Kaufmann M 307
Kieser A 139
Killander D 23
Kolch W 139
Krane J 282
Kvinnsland SK 282

Landry J 93
Latre ML 41
Leek RD 219
Lønning PE 282
Lynch HT 315
Lynch J 315

MacGrogan G 71
Marmé D 139
Marshall JL 253
Martiny-Baron G 139
Meli S 205
Missner SC 157
Molina R 41
Montserrat Daniels JJ 41
Morelli L 181
Moreno F 41
Morrow M 1

Olsson H 23

Pahisa J 41
Perry JJ 35
Ponta H 307

Rodenacker K 83
Rosen H 11
Rutquist L-E 83
Rydén S 23

Schulte AM 157
Seymour L 61
Sigurdsson H 23
Sinn H-P 307
Skarstein A 49
Skroch-Angel P 307
Søreide JA 49
Spona J 11
Stellmach V 119
Stierer M 11
Suzuki 193

Teicher BA 227
Têtu B 93
Thorpe PE 237
Toi M 193
Tominaga T 193
Trojani M 71
Tüchler H 11
Turner GDH 219

van Diest PJ 49
Varhaug JE 49
Velasco M 41
Verderio P 205
Volpert OV 119
von Minckwitz G 307
Voss A 83

Watson P 315
Weber R 11
Weidner N 169,205
Weiss RB 35
Wellstein A 157
Whitehouse RM 219

Zanón G 41
Zhang Z-C 299

Breast Cancer Research and Treatment **36**: 321-324, 1995.
© 1995 *Kluwer Academic Publishers. Printed in the Netherlands.*

Subject index, Volume 36

adhesion molecules
expression in tumor angiogenesis 219-226
adjuvant therapy
effect of PgR and S-phase on tamoxifen benefit 23-34
angiogenesis
as a prognostic factor and therapeutic target (introduction) 103-107
as a prognostic factor 193-204,205-217
historical review and clinical applications 109-118
microvessel density, methods for determination 169-180
prognostic impact by Chalkley counts 219-226
role of cell adhesion molecules 219-226
special issue 103-261
VEGF as a treatment target 127-137
angiogenesis factors
targeting pleiotrophin by antisense and by ribozymes 157-168
see also vascular endothelial growth factor
angiogenesis inhibitors
pentosan polysulfate, clinical experience 253-261
review of clinical data 253-261
thrombospondin, and restoration by wild-type p53 119-126
TNP-470 and minocycline potentiate chemosensitivity of EMT-6 mouse model 227-236
antiangiogenic agents
see angiogenesis inhibitors
antibodies
anti-endothelial monoclonal TEC-11 in targeted therapy 237-251
antiestrogens
tamoxifen actions compared with new antiestrogens 267-285
see also tamoxifen, toremifene
antigen retrieval
in IHC of fixed sections for p53 71-81
antigens
serum CEA and CA 15.3 in early detection of metastases 41-48
aromatase inhibitors
effects of exemestane on plasma lipids by NMR 287-297

biopsy
excisional vs. stereotactic core biopsy 1-9

CA 15.3 antigen
and CEA as serum markers for early detection of metastases 41-48
CAMs
see adhesion molecules
carcinoembryonic antigen (CEA)
and CA 15.3 as serum markers for early detection of metastases 41-48
CD44
splice variants and breast cancer metastasis 307-313
cost effectiveness
stereotactic core vs. excisional biopsy 1-9
cytometry
image cytometry — morphometric and textural features in prognosis 83-91

dexamethasone
effects on plasma lipids by NMR 287-297
diagnosis
accuracy of core biopsy 1-9
DNA histograms
by image cytometry in prognosis 83-91
drug resistance
failure of P-glycoprotein to predict anthracycline resistance 61-69
partial reversal by angiogenesis inhibitors in EMT-6 mouse model 227-236

EMT-6 mouse mammary tumor
angiogenesis inhibitors potentiate chemosensitivity 227-236
endocrine therapy
adjuvant tamoxifen benefit in ER+ node-positive patients over 50 49-53

endocrine therapy (cont.)
effect of PgR and S-phase on adjuvant tamoxifen benefit 23-34
effects on plasma lipids by NMR 287-297
endoglin
endothelial cell proliferation marker, as a therapeutic target 237-251
endometrial cancer
tamoxifen and other antiestrogens 267-285
endothelial cells
and VEGF in tumor angiogenesis 127-137
in tumors, as target for antibody-directed treatment 237-251
VEGF receptors and their regulation 139-155
estrogen receptor
and antiestrogens — William L. McGuire Memorial Lecture 267-285
negative correlation with P-glycoprotein 61-69
no response to toremifene in ER– metastatic breast cancer 35-40
in prognosis, DCC vs. IHC, with nuclear features 11-21

familial breast cancer
and zygosity determination in triplets 315-318
fibroblast growth factor, basic (bFGF)
as a determinant of angiogenic activity 181-192
inhibition of angiogenic role by pentosan polysulfate 253-261
flow cytometry
see S-phase

genetics
familial breast cancer and zygosity in triplets 315-318

heat shock proteins
hsp27 by IHC, negative result in prognosis 93-97
histologic grading
in prognosis, nuclear features, with ER 11-21
hormone therapy
see endocrine therapy
hsp27
see heat shock proteins

image analysis
potential automated angiogenesis measurement 181-192
image cytometry
morphometric and textural features in prognosis 83-91
interferon-α
as an angiogenesis inhibitor, clinical experience 257-258

Ki67
correlation with P-glycoprotein 61-69

laminin receptor
as a prognostic factor, with microvessel density and p53 205-217

mammographic abnormality
stereotactic core vs. excisional biopsy 1-9
markers
serum CEA and CA 15.3 in early detection of metastases 41-48
metastasis
association with CD44 splice variants 307-313
role of angiogenesis 109-118
microvessel density
as a prognostic factor 193-204
by Chalkley counts 219-226
computerized image analysis systems 181-192
methods for staining and counting 169-180
minocycline
as an angiogenesis inhibitor — partial reversal of drug resistance 227-236
morphometry
and textural features by image cytometry in prognosis 83-91
comparison of nuclear sampling methods for prognosis 55-60

neovascularization
regulation and role in tumor development 109-118
NMR spectroscopy
in detecting effects of endocrine therapies on plasma lipids 287-297
nuclear features
as principal prognostic subfactors of histologic grading 11-21
nuclear morphometry
comparison of nuclear sampling methods for prognosis 55-60

oxygenation
and radiation sensitization by angiogenesis inhibitors 227-236

P-glycoprotein
correlation with high Ki67 and low ER, but not anthracycline resistance 61-69
p53
and restoration of thrombospondin, a natural angiogenesis inhibitor 119-126
as a prognostic factor, with microvessel density and laminin receptor 205-217
by IHC in multivariate analysis of 942 cases 71-81
pentosan polysulfate
clinical experience as an angiogenesis inhibitor 253-261
phosphatidic acid
possible second messenger in non-ER actions of tamoxifen 299-306
plasma lipids
NMR detection of effects of endocrine therapies 287-297
plasminogen activator inhibitor (PAI-1)
measurement as a determinant of angiogenic activity 181-192
platelet factor 4
as an angiogenesis inhibitor, clinical experience 256-257
pleiotrophin
an angiogenesis factor from breast cancer cells 157-168
prediction of treatment response
effect of PgR and S-phase on adjuvant tamoxifen benefit 23-34
prevention
role of tamoxifen and new antiestrogens 267-285
progesterone receptor
effect with S-phase on adjuvant tamoxifen benefit 23-34
in prognosis, DCC vs. IHC, with nuclear features 11-21
prognostic factors
angiogenesis — by Chalkley counts 219-226
angiogenesis — microvessel density and VEGF 193-204
prognostic factors (con.t)
angiogenesis — microvessel density methods 169-180
DNA histogram by image cytometry 83-91
heat shock protein hsp27 by IHC, negative result 93-97
hormone receptors (by IHC) and nuclear features 11-21
image cytometry — morphometric and textural features 83-91
in small tumors, by image cytometry 83-91
microvessel density, with laminin receptor, p53 205-217
nuclear morphometry — comparison of sampling methods 55-60
p53 by IHC in multivariate analysis of 942 cases 71-81
peritumoral lymphatic vessel invasion, negative result 205-217

radiation sensitization
by angiogenesis inhibitors in EMT-6 mouse model 227-236
raloxifene
beneficial properties of a new antiestrogen 267-285

S-phase
effect with PgR on adjuvant tamoxifen benefit 23-34
selectins
expression in tumor angiogenesis 219-226
signal transduction
non-ER actions of tamoxifen via phospholipid second messengers 299-306
special issues
angiogenesis 103-261
stereotactic core biopsy
vs. excisional biopsy 1-9
stress-related proteins
see heat shock proteins
suramin
as an angiogenesis inhibitor, clinical experience 256

tamoxifen
adjuvant — benefit in ER+ node-positive patients over 50 49-53

tamoxifen (cont.)
adjuvant — effect of PgR and S-phase on benefit 23-34
and endometrial cancer 276-277
effects on plasma lipids by NMR 287-297
historical development and current use 267-285
non-ER actions via phospholipid second messengers 299-306
tecogalan
as an angiogenesis inhibitor, clinical experience 257
thrombospondin
as a natural angiogenesis inhibitor, restored by wild-type p53 119-126
TNP-470
as an angiogenesis inhibitor — partial reversal of drug resistance 227-236
toremifene
no response in ER– metastatic breast cancer 35-40
transforming growth factor beta (TGFβ)
as a determinant of angiogenic activity 181-192
tumor suppressor genes
see p53
tumor-associated antigens
serum CEA and CA 15.3 in early detection of metastases 41-48
urokinase-type plasminogen activator (uPA)
measurement as a determinant of angiogenic activity 181-192
vascular endothelial growth factor (VEGF)
association with microvessel density and prognosis 193-204
induction by hypoxia, growth factors, tumor promoters 139-155
measurement as a determinant of angiogenic activity 181-192
receptors on endothelial cells 139-155
role in tumor angiogenesis 127-137
vascular permeability factor (VPS)
see vascular endothelial growth factor
vascular targeting
as a therapeutic approach 237-251
William L. McGuire Memorial Lecture
studies on the estrogen receptor — V. Craig Jordan 267-285